TIM-1產(chǎn)品信息
英文名稱：T-cell immunoglobulin mucin receptor 1
中文名稱：T細(xì)胞免疫球蛋白粘蛋白受體-1
靶點(diǎn)別稱：HAVCR1,KIM1,TIM1,TIMD1
物種：Human
屬性：Protein
標(biāo)記：Unconjugated
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
TIM-1分子背景
Hepatitis A virus cellular receptor 1 is also known as HAVCR1, HAVCR, KIM1, TIM, TIM1, TIMD1, is widely expressed with highest levels in kidney and testis. The protein encoded by HAVCR1 gene is a membrane receptor for both human hepatitis A virus (HHAV) and TIMD4. The encoded protein may be involved in the moderation of asthma and allergic diseases. The reference genome represents an allele that retains a MTTVP amino acid segment that confers protection against atopy in HHAV seropositive individuals. Three transcript variants encoding the same protein have been found for this gene. HAVCR1 may play a role in T-helper cell development, the regulation of asthma and allergic diseases and in kidney injury and repair. In case of human hepatitis A virus (HHAV) infection, functions as a cell-surface receptor for the virus.
關(guān)鍵字： TIM-1;TIM-1蛋白;TIM-1重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。